# Effects of Cladribine Tablets on the PK of Microgynon®

> **NCT03745144** · PHASE1 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 28 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis (RMS)

## Interventions

- **DRUG:** Cladribine
- **DRUG:** Placebo
- **DRUG:** Microgynon®

## Key facts

- **NCT ID:** NCT03745144
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-17
- **Primary completion:** 2022-09-02
- **Final completion:** 2022-09-16
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03745144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03745144, "Effects of Cladribine Tablets on the PK of Microgynon®". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT03745144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*